Correlation Between Bayer AG and Bristol-Myers Squibb

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bayer AG and Bristol-Myers Squibb at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bayer AG and Bristol-Myers Squibb into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bayer AG and Bristol Myers Squibb, you can compare the effects of market volatilities on Bayer AG and Bristol-Myers Squibb and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bayer AG with a short position of Bristol-Myers Squibb. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bayer AG and Bristol-Myers Squibb.

Diversification Opportunities for Bayer AG and Bristol-Myers Squibb

-0.9
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Bayer and Bristol-Myers is -0.9. Overlapping area represents the amount of risk that can be diversified away by holding Bayer AG and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and Bayer AG is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bayer AG are associated (or correlated) with Bristol-Myers Squibb. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of Bayer AG i.e., Bayer AG and Bristol-Myers Squibb go up and down completely randomly.

Pair Corralation between Bayer AG and Bristol-Myers Squibb

Assuming the 90 days horizon Bayer AG is expected to under-perform the Bristol-Myers Squibb. But the pink sheet apears to be less risky and, when comparing its historical volatility, Bayer AG is 1.33 times less risky than Bristol-Myers Squibb. The pink sheet trades about -0.39 of its potential returns per unit of risk. The Bristol Myers Squibb is currently generating about 0.22 of returns per unit of risk over similar time horizon. If you would invest  84,500  in Bristol Myers Squibb on August 24, 2024 and sell it today you would earn a total of  16,055  from holding Bristol Myers Squibb or generate 19.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy90.91%
ValuesDaily Returns

Bayer AG  vs.  Bristol Myers Squibb

 Performance 
       Timeline  
Bayer AG 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Bayer AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Bristol Myers Squibb 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile primary indicators, Bristol-Myers Squibb reported solid returns over the last few months and may actually be approaching a breakup point.

Bayer AG and Bristol-Myers Squibb Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bayer AG and Bristol-Myers Squibb

The main advantage of trading using opposite Bayer AG and Bristol-Myers Squibb positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bayer AG position performs unexpectedly, Bristol-Myers Squibb can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will offset losses from the drop in Bristol-Myers Squibb's long position.
The idea behind Bayer AG and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Stocks Directory
Find actively traded stocks across global markets